Results 121 to 130 of about 5,494 (193)

Dead-Space Microdomains as Explicit Barriers to Extracellular Drug Transport in Alzheimer's Disease. [PDF]

Pharm Res
Charemis D, Lampropoulos D, Dimakopoulos Y, Sivolapenko G, Hadjinicolaou M.   +4 more
europepmc   +1 more source

A Narrative Review of Amyloid-β Monoclonal Antibodies for Alzheimer Disease: How Amyloid Species Engagement May Affect Clinical Outcomes. [PDF]

Neurologist
Caselli RJ, Geldmacher DS, Schilling TB.
europepmc   +1 more source

A reproducible three-dimensional model of human brain tissue to investigate physiological and disease-associated microglia phenotypes. [PDF]

Nat Neurosci
Klimmt J, Cardoso Gonçalves C, Montgomery JV, Müller SA, Bublitz M, Filser S, Paeger L, Nuscher B, Dannert A, Roeber S, Pravata V, Schifferer M, Shrouder JJ, Schulz N, González-Gallego J, Cappello S, Misgeld T, Plesnila N, Beltrán E, Herms J, De Domenico E, Beyer MD, Schultze JL, Haass C, Lichtenthaler SF, Carraro C, Paquet D.   +26 more
europepmc   +1 more source

Amyloid-beta-targeting monoclonal antibodies in early Alzheimer's disease: a cochrane review summary and appraisal for the neurological community. [PDF]

Neurol Sci
Santos DH, da Silva AMP.
europepmc   +1 more source

Antiamyloid Antibody Effects on Aβ-42 Protein Aggregates Profiled Using Nanospectroscopy. [PDF]

Chem Biomed Imaging
Kummer N, Cihova M, Nirmalraj PN.
europepmc   +1 more source

Treating dementia with brain amyloid medications. [PDF]

Can Fam Physician
Kolber MR, Korownyk CS.
europepmc   +1 more source

Anti-amyloid immunotherapy and brain volume trajectories in early-onset versus late-onset Alzheimer's disease. [PDF]

Alzheimers Dement (Amst)
Mehta RI, Jaisa-Aad M, Teixeira CVL, Worhunsky PD, Malone JE, Ward M, Keith CM, Phelps HE, Sharif K, Pockl S, Rajabalee N, Marano GD, Bojarski L, Smith S, Massey KM, Hatfield M, D'Haese PF, Rezai AR, Haut MW.   +18 more
europepmc   +1 more source

Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study. [PDF]

J Manag Care Spec Pharm
Dangpiaei S, Kamal KM, Shoair OA, Al-Mamun MA.   +3 more
europepmc   +1 more source

Aducanumab binding to Aβ_1-42 fibrils alters dynamics of the N-terminal tail while preserving the fibril core. [PDF]

Proc Natl Acad Sci U S A
Palani RS, Williams CG, Thacker D, Silvers R, Qian F, Weinreb PH, Mueller LJ, Linse S, Griffin RG.   +8 more
europepmc   +1 more source

Sex differences in efficacy/safety of anti-amyloid-beta monoclonal antibodies for the treatment of Alzheimer's disease. [PDF]

Transl Clin Pharmacol
Lim S, Lee HW, Yoon S, Han JW, Chung JY, Yoon S.   +5 more
europepmc   +1 more source